2197 — Clover Biopharmaceuticals Share Price
0.000.00%
Last trade - 00:00- HK$271.09m
- -HK$88.62m
- CNY38.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.63 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -2336.53% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | 39.26 | 38.42 | 2,364.23 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Clover Biopharmaceuticals Ltd is a China-based company mainly engaged in pharmaceutical business. The Company's main business is the development of new vaccines and biotherapeutic candidates for infectious diseases, cancer and autoimmune diseases. The Company's products are mainly used to treat the new coronavirus, malignant ascites, and ankylosing spondylitis.
Directors
- Peng Liang CHM (60)
- Joshua G Liang CEO (29)
- Phillip Eric Lee CFO (34)
- Xiaobing Li EVP (53)
- Michael Berry CTO (56)
- Krex Brian GCN (54)
- Philippe Bishop OTH (53)
- Htay Htay Han OTH (53)
- Hing Ling Chau SEC (45)
- Dong Lyu NED (46)
- Xiaodong Wang NED (58)
- Ting Xiao NED (34)
- Jeffrey Farrow NID (59)
- Thomas Leggett NID
- Xiang Liao NID (56)
- Xiaobin Wu NID (59)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 31st, 2018
- Public Since
- November 5th, 2021
- No. of Employees
- 300
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,297,062,429
- Address
- Room 1901,, SHANGHAI
- Web
- https://www.cloverbiopharma.com
- Phone
- Contact
- Naomi Eichenbaum
- Auditors
- Ernst & Young
Upcoming Events for 2197
Similar to 2197
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the Clover Biopharmaceuticals share price?
As of Today at 19:59 UTC, shares in Clover Biopharmaceuticals are trading at HK$0.21. This share price information is delayed by 15 minutes.
How has the Clover Biopharmaceuticals share price performed this year?
Shares in Clover Biopharmaceuticals last closed at HK$0.21 and the price had moved by -36.67% over the past 365 days. In terms of relative price strength the Clover Biopharmaceuticals share price has underperformed the FTSE Developed Asia Pacific Index by -35.94% over the past year.
What are the analyst and broker recommendations for Clover Biopharmaceuticals?
The overall consensus recommendation for Clover Biopharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Clover Biopharmaceuticals dividend yield?
Clover Biopharmaceuticals does not currently pay a dividend.
Does Clover Biopharmaceuticals pay a dividend?
Clover Biopharmaceuticals does not currently pay a dividend.
When does Clover Biopharmaceuticals next pay dividends?
Clover Biopharmaceuticals does not currently pay a dividend.
How do I buy Clover Biopharmaceuticals shares?
To buy shares in Clover Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Clover Biopharmaceuticals?
As of the previous close price of HK$0.21, shares in Clover Biopharmaceuticals had a market capitalisation of HK$271.09m.
Where are Clover Biopharmaceuticals shares listed?
Here are the trading details for Clover Biopharmaceuticals:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2197
What kind of share is Clover Biopharmaceuticals?
Based on an overall assessment of its quality, value and momentum Clover Biopharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Clover Biopharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Clover Biopharmaceuticals is HK$3.96. That is 1792.79% above the last closing price of HK$0.21.
Analysts covering Clover Biopharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of CNY1.14 for the next financial year.
Find out moreWhat is the trend in the Clover Biopharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clover Biopharmaceuticals. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -28.56%.
As of the last closing price of HK$0.21, shares in Clover Biopharmaceuticals were trading -24.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Clover Biopharmaceuticals PE Ratio?
The Clover Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.21.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Clover Biopharmaceuticals?
Clover Biopharmaceuticals' management team is headed by:
- Peng Liang - CHM
- Joshua G Liang - CEO
- Phillip Eric Lee - CFO
- Xiaobing Li - EVP
- Michael Berry - CTO
- Krex Brian - GCN
- Philippe Bishop - OTH
- Htay Htay Han - OTH
- Hing Ling Chau - SEC
- Dong Lyu - NED
- Xiaodong Wang - NED
- Ting Xiao - NED
- Jeffrey Farrow - NID
- Thomas Leggett - NID
- Xiang Liao - NID
- Xiaobin Wu - NID